Best Diversified Pharmaceuticals Companies in San Diego, United States

Producer of cellular agricultural products

Pioneering small molecule therapies for cancer and inflammatory bowel disease. This company is dedicated to discovering and developing novel therapies for cancer and other serious diseases. They focus on small molecule drugs that target novel members of the nuclear receptor superfamily, a proven class for treating inflammation, oncology, and metabolic disorders. Their pipeline includes first-in-class programs in preclinical and clinical development, with a focus on oncology (including adrenal, head & neck, and squamous cancers) and inflammatory bowel disease (ulcerative colitis and Crohn’s disease). They actively engage with clinical, scientific, investment, and patient communities to advance new therapeutic approaches. Their mission is translational drug discovery and development, leading to first-in-class therapeutics. They are drug hunters committed to bringing innovative treatments to patients in need.

Biopharmaceutical company pioneering targeted protein degradation for innovative medicines, dedicated to developing first-in-class treatments for diseases lacking effective therapeutic approaches. They utilize a proprietary technology platform featuring novel E3 ligands to build the next generation of targeted protein degraders. The mission is to create new drugs for diseases that currently lack effective therapies, expanding the drug design paradigm to drug the "undruggable." They are focused on protein degradation, degrader-antibody conjugates, and novel E3 ligands, leveraging their expertise in UPS and E3s. The company is developing a pipeline of innovative medicines for cancer and other debilitating diseases, pushing the limits of what is possible in medicine.

Funding rounds

• May 2023Series B$40M
• Feb 2021Series B$50M
• Apr 2019Series A$16M
• Mar 2018Seed$15M

Founders & team

Yue XiongCo-FounderJian JinCo-FounderYing LuoCEO

Investors

South China Venture Capital, Octagon Capital Advisors, Heights Capital Management, MSA Novo, 3E BioVentures, Sincere Capital

Tech stack

AngularCart FunctionalityCore-JsGoogle AnalyticsGoogle Font ApiHsts

Developer of small molecule therapeutics platform designed to reprogram protein folding for the treatment of various systemic amyloid diseases and protein misfolding diseases. The company's drug discovery platform in order to address the protein misfolding problem modulates the energetics of proteins using pharmacological chaperones and/or modulates the cellular folding, secretory and stress pathways, enabling doctors to obtain disease-modifying therapeutics.

Emerald Health Pharmaceuticals (EHP) is a part of Emerald Health Sciences (EHS), focuses on discovering, developing and commercializing proprietary cannabinoid-derived medicines. It has two proprietary drugs in preclinical development. EHP-101 is derived from cannabidiol (CBD) for the treatment of multiple sclerosis & scleroderma and EHP-102 is derived from cannabigerol (CBG) is for the treatment of Huntington’s and Parkinson’s disease. The postulated MOA of these drugs is dual PPARγ and CB2 agonist. EHP-1 got an orphan drug designation for systemic scleroderma by US FDA, recently.

Premier biopharmaceutical company dedicated to innovative medicines and healthcare solutions. It focuses on discovering, developing, and manufacturing a wide range of medicines and vaccines. The company is committed to advancing science and improving health outcomes for people worldwide. Its areas of focus include internal medicine, inflammation and immunology, vaccines, and oncology, addressing various diseases and conditions. It offers diverse products, from branded and generic drugs to biologics and biosimilars, ensuring quality and medicine safety. The company engages in research and development, partnering with patients and healthcare professionals. It is dedicated to global health initiatives, ethical practices, and environmental sustainability. It provides resources for patients, professionals, and investors, fostering transparency and accessibility.

Developer of immunology therapeutics for cancer and inflammatory diseases. The company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease, rosnilimab, its PD-1 agonist, for the treatment of moderate-to-severe rheumatoid arthritis, and ANB032, its BTLA agonist, for the treatment of moderate-to-severe atopic dermatitis.

R&D company focused on manufacturing disease-modifying antibodies for multiple therapeutics areas

Funding rounds

• Dec 2021Series A$31M

Founders & team

Ciara KennedyPresident & Chief Executive Officer

Investors

New Enterprise Associates, Arix Bioscience, Biovision Ventures, Lundbeck Foundation

Antibody therapeutics to G-Protein Coupled Receptors targets validated with small molecules. The company focuses on the discovery and development of biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis, and nonalcoholic steatohepatitis. The company develops novel antibodies that represent antibody therapeutics to G-Protein Coupled Receptors targets validated with small molecules.

TargeGen, a vascular biology-focused biopharmaceutical company, discovers and develops small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis), and inflammation. It offers its products for the treatment of human diseases, such as heart attack, cancer, and eye diseases; vascular leakage, edema, and the unwanted growth of new blood vessels; pleural effusions, arthritis, pulmonary edema, transplant ischemia, ARDS, brain inflammation, hypovolemia (acute blood loss) CNS disorders, and other serious medical conditions. It serves macular degeneration, diabetic macular edema, and diabetic retinopathy markets. It was acquired by Sanofi-Aventis in 2010.

Funding rounds

• Sep 2009Series D$3.7M
• Jul 2007Series D$40M
• Jan 2004Series B$30M

Founders & team

Peter Herstall UlrichFounder & CEO

Investors

Forward Ventures, BB Biotech Ventures, Chicago Growth Partners, CTI Life Sciences Fund, Enterprise Partners Venture Capital, VantagePoint Capital Partners

Mast Therapeutics (which merged with Savara in April 2017), was developing therapies for serious or life-threatening diseases. The company used its Molecular Adhesion and Sealant Technology (MAST) platform to develop the therapies. The company's lead candidate, Vepoloxamer, is in Phase 3 clinical development for the treatment of vaso-occlusive crisis in patients with sickle cell disease and has finished enrollment for Phase 3 study in February 2016. Vepoloxamer is also in Phase 2 clinical development for the treatment of patients with heart failure. The company went public in 2004. The company ceased to exist post its merger with Savara, a pharma company engaged in developing novel treatments for serious or life-threatening rare respiratory diseases.

Providing solutions for targeting and delivering nucleic acid therapeutics. It focuses on solving the problem of targeting and delivery of nucleic acid therapeutics. The company is developing small, cell-permeable RNAi pro-drugs that can enter many different cell types and deliver on the promise of RNAi therapeutics.